Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

PHASE2CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
Rosacea
Interventions
DRUG

CD07805/47 Gel

CD07805/47 Gel 0.5% QD

DRUG

Vehicle Gel

Vehicle Gel QD

DRUG

CD07805/47 Gel

CD07805/47 Gel 0.18% QD

DRUG

CD07805/47 Gel

CD07805/47 Gel 0.18% BID

DRUG

Vehicle Gel

Vehicle Gel BID

Trial Locations (20)

10021

Skin Specialty Group, New York

18201

DermDox, Hazleton

19034

Philadelphia Institute of Dermatology, Fort Washington

24501

The Education & Research Foundation, Lynchburg

27262

Dermatology Consulting Services, High Point

28207

Dermatology Laser & Vein Specialists, Charlotte

29007

Palmetto Clinical Trial Services, LLC, Greenville

30263

Meda Phase, Inc, Newnan

37902

The Skin Wellness Center, Knoxville

40202

Dermatology Specialists PC, Louisville

53719

Madison Skin & Research, Madison

55432

Minnesota Clinical Study Center, Fridley

63117

Central Dermatology, PC, St Louis

71913

Burke Pharmaceutical Research, Hot Springs

75230

Dermatology Treatment & Research Center, Dallas

76011

Arlington Center for Dermatology, Arlington

97210

Oregon Dermatology & Research Center, Portland

97223

Oregon Medical Research, Portland

99204

Premier Clinical Research, Spokane

94143-0660

University of California at San Francisco, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY